http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 01 Jun 2026 09:00:49 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/FDA/Anixa+Biosciences+reports+patient+survival+data+from+cancer+therapy+trial/26465949.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) reported survival data from its ongoing Phase 1 clinical trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer, according to a company statement.</p> <p>The data were presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting on May 7. Trial participants lived beyond their median expected survival of three to four months based on disease stage and prior therapy history.</p> <p>One patient survived 28 months following treatment, while three patients survived greater than one year at 18, 17 and 17 months respectively. Four additional patients survived 11, 11, 8 and 7 months respectively. http://www.streetinsider.com/FDA/Anixa+Biosciences+reports+patient+survival+data+from+cancer+therapy+trial/26465949.html Mon, 11 May 2026 08:55:13 -0400 ANIX O.00049302 http://www.streetinsider.com/FDA/Anixa+Biosciences+reports+patient+survival+data+from+cancer+therapy+trial/26465949.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) reported survival data from its ongoing Phase 1 clinical trial of lira-cel, a CAR-T therapy for recurrent ovarian cancer, according to a company statement.</p> <p>The data were presented at the International Society for Cell & Gene Therapy 2026 Annual Meeting on May 7. Trial participants lived beyond their median expected survival of three to four months based on disease stage and prior therapy history.</p> <p>One patient survived 28 months following treatment, while three patients survived greater than one year at 18, 17 and 17 months respectively. Four additional patients survived 11, 11, 8 and 7 months respectively. http://www.streetinsider.com/FDA/Anixa+Biosciences+reports+patient+survival+data+from+cancer+therapy+trial/26465949.html Mon, 11 May 2026 08:55:13 -0400 ANIX O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html <div class="xn-content"> <p class="prntac"><i>Multiple patients have survived substantially beyond expected median survival, including one<br />patient who survived 28 months and several patients who remain alive with continued follow-up</i></p><p class="prntac"><i>Lira-cel clinical trial featured in presentation at the <span>International Society for Cell &amp; Gene Therapy</span><br />2026 Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>May 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4684837-1&amp;h=2795936732&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html Mon, 11 May 2026 08:55:00 -0400 ANIX O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html <div class="xn-content"> <p class="prntac"><i>Multiple patients have survived substantially beyond expected median survival, including one<br />patient who survived 28 months and several patients who remain alive with continued follow-up</i></p><p class="prntac"><i>Lira-cel clinical trial featured in presentation at the <span>International Society for Cell &amp; Gene Therapy</span><br />2026 Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>May 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4684837-1&amp;h=2795936732&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html Mon, 11 May 2026 08:55:00 -0400 ANIX O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html <div class="xn-content"> <p class="prntac"><i>Multiple patients have survived substantially beyond expected median survival, including one<br />patient who survived 28 months and several patients who remain alive with continued follow-up</i></p><p class="prntac"><i>Lira-cel clinical trial featured in presentation at the <span>International Society for Cell &amp; Gene Therapy</span><br />2026 Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>May 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4684837-1&amp;h=2795936732&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html Mon, 11 May 2026 08:55:00 -0400 ANIX O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html <div class="xn-content"> <p class="prntac"><i>Multiple patients have survived substantially beyond expected median survival, including one<br />patient who survived 28 months and several patients who remain alive with continued follow-up</i></p><p class="prntac"><i>Lira-cel clinical trial featured in presentation at the <span>International Society for Cell &amp; Gene Therapy</span><br />2026 Annual Meeting</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>May 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4684837-1&amp;h=2795936732&amp;u=https%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced updated positive survival observations from its ongoing Phase 1 clinical trial of liraltagene autoleucel, or http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Reports+Updated+Positive+Survival+Observations+from+Ongoing+Phase+1+Trial+of+Lira-cel+Ovarian+Cancer+CAR-T+Therapy/26465947.html Mon, 11 May 2026 08:55:00 -0400 ANIX O.00049302 http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+Anixa+Biosciences%2C+Inc./26467228.html <div class="xn-content"> <p>In the news release, Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy, issued <chron>11-May-2026</chron> by <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:</p> <h3>Anixa Biosciences Reports Updated Positive Survival Observations from Ongoing Phase 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy</h3> <p class="prntac"><i>Multiple patients have survived substantially beyond expected median survival, including one<br />patient who survived 28 months and several patients who remain alive with continued http://www.streetinsider.com/Press+Releases/C+O+R+R+E+C+T+I+O+N+--+Anixa+Biosciences%2C+Inc./26467228.html Mon, 11 May 2026 08:55:00 -0400 ANIX O.00049302